Abelacimab

Abelacimab (MAA868) is a fully human IgG1 monoclonal antibody that binds with high affinity to the catalytic structural domain of FXI and locks it in the zymogen conformation, thereby preventing its activation by FXIIa or thrombin. Abelacimab can be used in thromboembolic disease studies[1][2].

Product Specifications

CAS Number

[2098724-83-3]

Product Name Alternative

MAA868

UNSPSC

12352203

Target

Factor Xa

Type

Inhibitory Antibodies

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/abelacimab.html

Purity

98.63

Solubility

10 mM in DMSO

Smiles

[Abelacimab]

Molecular Weight

(147.32 kDa)

References & Citations

[1]Alexander W Koch, et al. MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans. Blood. 2019 Mar 28;133 (13) :1507-1516.|[2]Elena Campello, et al. Clinical Pharmacology of Factor XI Inhibitors: New Therapeutic Approaches for Prevention of Venous and Arterial Thrombotic Disorders. J Clin Med. 2022 Oct 26;11 (21) :6314.